Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort

Gregg Eure, Raymond Germany, Robert Given, Ruixiao Lu, Alan W Shindel, Megan Rothney, Richard Glowacki, Jonathan Henderson, Tim Richardson, Evan Goldfischer, Phillip G. Febbo, Bela S. Denes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To study the impact of genomic testing in shared decision making for men with clinically low-risk prostate cancer (PCa). Materials and Methods: Patients with clinically low-risk PCa were enrolled in a prospective, multi-institutional study of a validated 17-gene tissue-based reverse transcription polymerase chain reaction assay (Genomic Prostate Score [GPS]). In this paper we report on outcomes in the first 297 patients enrolled in the study with valid 17-gene assay results and decision-change data. The primary end points were shared decision on initial management and persistence on active surveillance (AS) at 1 year post diagnosis. AS utilization and persistence were compared with similar end points in a group of patients who did not have genomic testing (baseline cohort). Secondary end points included perceived utility of the assay and patient decisional conflict before and after testing. Results: One-year results were available on 258 patients. Shift between initial recommendation and shared decision occurred in 23% of patients. Utilization of AS was higher in the GPS-tested cohort than in the untested baseline cohort (62% vs 40%). The proportion of men who selected and persisted on AS at 1 year was 55% and 34% in the GPS and baseline cohorts, respectively. Physicians reported that GPS was useful in 90% of cases. Mean decisional conflict scores declined in patients after GPS testing. Conclusion: Patients who received GPS testing were more likely to select and persist on AS for initial management compared with a matched baseline group. These data indicate that GPS help guide shared decisions in clinically low-risk PCa.

Original languageEnglish (US)
JournalUrology
DOIs
StateAccepted/In press - 2017
Externally publishedYes

Fingerprint

Prostate
Genes
Prostatic Neoplasms
Reverse Transcription
Decision Making
Research Design
Physicians
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Urology

Cite this

Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice : Results of an Interim Analysis in an Observational Cohort. / Eure, Gregg; Germany, Raymond; Given, Robert; Lu, Ruixiao; Shindel, Alan W; Rothney, Megan; Glowacki, Richard; Henderson, Jonathan; Richardson, Tim; Goldfischer, Evan; Febbo, Phillip G.; Denes, Bela S.

In: Urology, 2017.

Research output: Contribution to journalArticle

Eure, G, Germany, R, Given, R, Lu, R, Shindel, AW, Rothney, M, Glowacki, R, Henderson, J, Richardson, T, Goldfischer, E, Febbo, PG & Denes, BS 2017, 'Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort', Urology. https://doi.org/10.1016/j.urology.2017.02.052
Eure, Gregg ; Germany, Raymond ; Given, Robert ; Lu, Ruixiao ; Shindel, Alan W ; Rothney, Megan ; Glowacki, Richard ; Henderson, Jonathan ; Richardson, Tim ; Goldfischer, Evan ; Febbo, Phillip G. ; Denes, Bela S. / Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice : Results of an Interim Analysis in an Observational Cohort. In: Urology. 2017.
@article{5f335c7552ef4befa66ff8f93a5cb120,
title = "Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort",
abstract = "Objective: To study the impact of genomic testing in shared decision making for men with clinically low-risk prostate cancer (PCa). Materials and Methods: Patients with clinically low-risk PCa were enrolled in a prospective, multi-institutional study of a validated 17-gene tissue-based reverse transcription polymerase chain reaction assay (Genomic Prostate Score [GPS]). In this paper we report on outcomes in the first 297 patients enrolled in the study with valid 17-gene assay results and decision-change data. The primary end points were shared decision on initial management and persistence on active surveillance (AS) at 1 year post diagnosis. AS utilization and persistence were compared with similar end points in a group of patients who did not have genomic testing (baseline cohort). Secondary end points included perceived utility of the assay and patient decisional conflict before and after testing. Results: One-year results were available on 258 patients. Shift between initial recommendation and shared decision occurred in 23{\%} of patients. Utilization of AS was higher in the GPS-tested cohort than in the untested baseline cohort (62{\%} vs 40{\%}). The proportion of men who selected and persisted on AS at 1 year was 55{\%} and 34{\%} in the GPS and baseline cohorts, respectively. Physicians reported that GPS was useful in 90{\%} of cases. Mean decisional conflict scores declined in patients after GPS testing. Conclusion: Patients who received GPS testing were more likely to select and persist on AS for initial management compared with a matched baseline group. These data indicate that GPS help guide shared decisions in clinically low-risk PCa.",
author = "Gregg Eure and Raymond Germany and Robert Given and Ruixiao Lu and Shindel, {Alan W} and Megan Rothney and Richard Glowacki and Jonathan Henderson and Tim Richardson and Evan Goldfischer and Febbo, {Phillip G.} and Denes, {Bela S.}",
year = "2017",
doi = "10.1016/j.urology.2017.02.052",
language = "English (US)",
journal = "Urology",
issn = "1527-9995",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice

T2 - Results of an Interim Analysis in an Observational Cohort

AU - Eure, Gregg

AU - Germany, Raymond

AU - Given, Robert

AU - Lu, Ruixiao

AU - Shindel, Alan W

AU - Rothney, Megan

AU - Glowacki, Richard

AU - Henderson, Jonathan

AU - Richardson, Tim

AU - Goldfischer, Evan

AU - Febbo, Phillip G.

AU - Denes, Bela S.

PY - 2017

Y1 - 2017

N2 - Objective: To study the impact of genomic testing in shared decision making for men with clinically low-risk prostate cancer (PCa). Materials and Methods: Patients with clinically low-risk PCa were enrolled in a prospective, multi-institutional study of a validated 17-gene tissue-based reverse transcription polymerase chain reaction assay (Genomic Prostate Score [GPS]). In this paper we report on outcomes in the first 297 patients enrolled in the study with valid 17-gene assay results and decision-change data. The primary end points were shared decision on initial management and persistence on active surveillance (AS) at 1 year post diagnosis. AS utilization and persistence were compared with similar end points in a group of patients who did not have genomic testing (baseline cohort). Secondary end points included perceived utility of the assay and patient decisional conflict before and after testing. Results: One-year results were available on 258 patients. Shift between initial recommendation and shared decision occurred in 23% of patients. Utilization of AS was higher in the GPS-tested cohort than in the untested baseline cohort (62% vs 40%). The proportion of men who selected and persisted on AS at 1 year was 55% and 34% in the GPS and baseline cohorts, respectively. Physicians reported that GPS was useful in 90% of cases. Mean decisional conflict scores declined in patients after GPS testing. Conclusion: Patients who received GPS testing were more likely to select and persist on AS for initial management compared with a matched baseline group. These data indicate that GPS help guide shared decisions in clinically low-risk PCa.

AB - Objective: To study the impact of genomic testing in shared decision making for men with clinically low-risk prostate cancer (PCa). Materials and Methods: Patients with clinically low-risk PCa were enrolled in a prospective, multi-institutional study of a validated 17-gene tissue-based reverse transcription polymerase chain reaction assay (Genomic Prostate Score [GPS]). In this paper we report on outcomes in the first 297 patients enrolled in the study with valid 17-gene assay results and decision-change data. The primary end points were shared decision on initial management and persistence on active surveillance (AS) at 1 year post diagnosis. AS utilization and persistence were compared with similar end points in a group of patients who did not have genomic testing (baseline cohort). Secondary end points included perceived utility of the assay and patient decisional conflict before and after testing. Results: One-year results were available on 258 patients. Shift between initial recommendation and shared decision occurred in 23% of patients. Utilization of AS was higher in the GPS-tested cohort than in the untested baseline cohort (62% vs 40%). The proportion of men who selected and persisted on AS at 1 year was 55% and 34% in the GPS and baseline cohorts, respectively. Physicians reported that GPS was useful in 90% of cases. Mean decisional conflict scores declined in patients after GPS testing. Conclusion: Patients who received GPS testing were more likely to select and persist on AS for initial management compared with a matched baseline group. These data indicate that GPS help guide shared decisions in clinically low-risk PCa.

UR - http://www.scopus.com/inward/record.url?scp=85023602714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023602714&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2017.02.052

DO - 10.1016/j.urology.2017.02.052

M3 - Article

C2 - 28454985

AN - SCOPUS:85023602714

JO - Urology

JF - Urology

SN - 1527-9995

ER -